67Cu MeCOSar Octreotate - Clarity Pharmaceuticals

Drug Profile

67Cu MeCOSar Octreotate - Clarity Pharmaceuticals

Alternative Names: 67-Cu-SARTATE; copper-67 labelled MeCOSar-Tyr3-octreotate; SARTATE™ KIDS Therapy - Clarity Pharmaceuticals; SARTATE™ NETs Therapy - Clarity Pharmaceuticals; SARTATE™ Therapy - Clarity Pharmaceuticals

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clarity Pharmaceuticals
  • Class Antibodies; Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours
  • Preclinical Neuroblastoma

Most Recent Events

  • 26 Sep 2017 Clarity Pharmaceuticals completes the phase IIa trial in Neuroendocrine tumours in Australia before September 2017 (Clarity Pharmaceuticals pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top